UK pharmaceutical giant GlaxoSmithKline kept the dangers of its top-selling diabetes drug Avandia out of the public eye and ghostwrote scientific articles about it, US lawmakers charged Tuesday.
The damning letter and the allegations in the Wall Street Journal came as a panel of experts began considering whether Glaxo's star diabetes drug should be pulled from the market.
"The documents we uncovered in our investigation will help arm the FDA with the best information possible as it evaluates Avandia's safety," Baucus said.
The FDA is not bound by recommendations made by the panels of experts it convenes to take a decision on a drug, but usually follows their advice. - (Sapa, July 2010)